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Colorectal carcinoma (CRC) is the third-most commonly
diagnosed cancer in the U.S., and the third-most com-
mon cause of cancer death. There were 136,830 new
cases of CRC and 50,310 deaths due to CRC in 2014. For
patients with unresectable metastatic disease, initial ther-
apy commonly consists of chemotherapy combinations of
Fluoropyrimidine agents, Oxaliplatin and Irinotecan with
or without Bevacizumab or Cetuximab. Nonetheless, the
prognosis of patients with metastatic CRC remains extre-
mely poor overall, with 5-year survival rates estimated to
be as low as 6-8%. There remains an urgent need, there-
fore, for new approaches for the treatment of patients
with CRC.
Glycoprotein A33 (gpA33) is a 43 kDa membrane-
bound glycoprotein with expression restricted to the sur-
face of normal human colon and small bowel epithelial
cells. In addition, the gpA33 antigen is homogeneously
expressed at high levels in > 95% of primary and meta-
static human CRC. These observations suggest that gpA33
that could be an attractive target for the immunotherapy
of CRC. The Dual-Affinity Re-Targeting (DART®) tech-
nology, is a proprietary antibody-based platform that has
been designed to engage multiple targets with a single
molecule. MGD007 is a novel gpA33x CD3 DART protein
that targets gpA33-positive cells for recognition and elimi-
nation by co-engagement of CD3-expressing T lympho-
cytes. MGD007 mediates redirected T cell killing of
gpA33-expressing CRC cell lines in vitro and regression of
transplantable CRC cell line xenografts in preclinical
tumor models. Preclinical toxicology studies in cynomol-
gus monkeys demonstrated that MGD007 could be admi-
nistered safely with a pharmacokinetic profile supportive
of repeat dosing on a weekly basis.
We have designed a two-arm, Phase I dose-escalation
study of MDG007 administered intravenously in patients
with metastatic relapsed/refractory CRC. The study will
employ a 3+3+3 design to explore the safety, PK, immu-
noregulatory activity and preliminary anti-tumor activity
of MGD007 administered on either once-weekly or
every three week schedules of administration. Projected
doses to be tested will range from 0.6-150 mcg/kg. This
study represents the first clinical evaluation of DART
molecules in patients with solid tumors.
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